Skip to main content
. 2018 Dec 4;145(3):599–607. doi: 10.1007/s00432-018-2810-6

Fig. 3.

Fig. 3

Predictive value for tamoxifen benefit of PTPN2 protein expression. Distant recurrence-free survival (DRFS) for breast cancer patients treated with tamoxifen (Tam) vs no tamoxifen in relation low PTPN2 protein in oestrogen receptor-positive (ER+) tumours (a), high PTPN2 protein expression in ER + tumours (b), low PTPN2 protein expression in ER + tumours with grade 2 or 3 (c), and high PTPN2 protein expression in ER + tumours with grade 2 or 3 (d). P values were estimated with the log rank test